Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 98.56
- Piotroski Score 2.00
- Grade Buy
- Symbol (GLSI)
- Company Greenwich LifeSciences, Inc.
- Price $12.34
- Changes Percentage (-1.79%)
- Change -$0.23
- Day Low $12.20
- Day High $13.17
- Year High $21.44
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.71
- Trailing P/E Ratio -20.25
- Forward P/E Ratio -20.25
- P/E Growth -20.25
- Net Income $-8,891,803
Income Statement
Quarterly
Annual
Latest News of GLSI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Greenwich LifeSciences, Inc. (GLSI) Stock Price, News, Quote & History - Yahoo Finance
Greenwich LifeSciences expands clinical trial sites to Spain with GEICAM partnership for their Phase III trial evaluating GLSI-100 to prevent breast cancer recurrences....
By Yahoo! Finance | 1 month ago -
Insider Buying: CEO and CFO Snehal Patel Acquires Shares of Greenwich LifeSciences Inc (GLSI)
Snehal Patel, CEO, CFO, and 10% Owner of Greenwich LifeSciences Inc (NASDAQ:GLSI), bought 174,825 shares, increasing total ownership to 5,525,602 shares. The company focuses on breast cancer and immun...
By Yahoo! Finance | 5 months ago
